Dwarfism
Also known as: Little person
Methodology & AI Transparency ⓘ
Dwarfism Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: People with dwarfism have short stature.
- 2 Real-world patient consensus: Clinical coding for Dwarfism uses ICD-10 M25.1 across Arthritis & Joints specialty care.
- 3 Typical cash cost range: Workup highlights for Dwarfism (M25.1): urate-lowering titration [Dwarfism M25.1].
- 4 Top reported side effects / signs: Follow-up benchmark in Dwarfism: maintaining Serum Uric Acid in Dwarfism (M25.1: (Gout Target)) within < 6.0 mg/dL (< 5.0 mg/dL with tophi) (M25.1).
Ask our AI Specialists anything about Dwarfism
What Is Dwarfism?
People with dwarfism have short stature. This means that their height is under 4' 10" as an adult. They are usually of normal intelligence. Dwarfism most often does happen in families where both parents are of average height. More than 300 different conditions can cause dwarfism. Achondroplasia is the most common type of dwarfism. Achondroplasia is a genetic condition that affects about 1 in 15,000 to 1 in 40,000 people. It makes your arms and legs short in comparison to your head and trunk. You may also have a larger head and weak muscle tone. Other genetic conditions, kidney disease, and problems with metabolism or hormones can also cause dwarfism.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Dwarfism (code M25.1) is monosodium urate or in Dwarfism (M25.1: calcium pyrophosphate crystal), Cross-referenced with NIH MeSH (Dwarfism), which Osteoarthritis, Gout & Joint Pain clinicians address while surveilling Serum Uric Acid in Dwarfism (M25.1: (Gout Target)) (< 6.0 mg/dL (< 5.0 mg/dL with tophi) (M25.1)).
Common Symptoms & Clinical Signs
- • Presentation of Dwarfism (M25.1): localized tendon or in Dwarfism (M25.1: bursa tenderness limiting)
- • Secondary Dwarfism clinical sign: activity-related deep aching in Dwarfism (M25.1: joint pain in)
- • Symptom flares in Dwarfism correlating with Serum Uric Acid in Dwarfism (M25.1: (Gout Target)) deviation outside < 6.0 mg/dL (< 5.0 mg/dL with tophi) (M25.1)
- • Functional arthritis & joints impact requiring urate-lowering titration [Dwarfism M25.1] evaluation (M25.1)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Dwarfism Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | M25.1 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Osteoarthritis, Gout & Joint Pain | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Serum Uric Acid in Dwarfism (M25.1: (Gout Target)) | < 6.0 mg/dL (< 5.0 mg/dL with tophi) (M25.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: hs-CRP & Erythrocyte in Dwarfism (M25.1: Sedimentation Rate) | hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (M25.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Weight-Bearing Joint Radiograph [Dwarfism M25.1] | Preserved joint-space width (M25.1) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Dwarfism
Treatment selection for Dwarfism depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Dwarfism)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Trajectory of clinical responses in patients with early autoimmune joint pain: What a 451-Participant Study Found A high proportion of individual patients achieving clinical endpoints at IP week 24 with abatacept + methotrexate sustained their responses through week 52. Arthritis research & therapy • 2023-04-22 • Phase III Randomized Trial | N = 451 | 93/100 | PMID 37087459 ↗ |
| Can This Approach Help? Inside the Latest Research on Exposure-Response Analysis of Tofacitinib in Active Psoriatic Arthritis: Results The proportions of patients experiencing a decrease in Hgb of >2 g/dL were similar with tofacitinib 5 mg twice daily or placebo. Journal of clinical pharmacology • 2025-03-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39453735 ↗ |
| Can This Approach Help? Inside the Latest Research on Disease-Worsening Following Withdrawal of Etanercept or Methotrexate on Etanercept single-drug treatment showed benefit over methotrexate in maintaining PRO scores. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases • 2023-01-01 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 36459119 ↗ |
| Managing GHD: Can Effective GH Replacement With Somapacitan Make a Real Difference? (What New Research Reveals) Somapacitan in children with GHD showed sustained efficacy and tolerability for 2 years, and after switching from daily GH. The Journal of clinical endocrinology and metabolism • 2023-11-17 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 37406251 ↗ |
| Can This Approach Help? Inside the Latest Research on Gene Expression Signatures Predict First-Year Response to Somapacitan Treatment Pretreatment transcriptome predicts first-year growth response in somapacitan-treated children with GHD. The Journal of clinical endocrinology and metabolism • 2024-04-19 • Phase III Randomized Trial | N = 76 | 82/100 | PMID 38066644 ↗ |
Dwarfism Patient Community & “People Like Me” Threads
Filter Dwarfism community threads and patient logs by age, biological sex, dosage, and treatment duration.